{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.7","upperLimit":"99.8","value":"90.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"A participant was said to have a confirmed HR if all the criteria for HR were fulfilled again at least 28 days after they first met with no concomitant use of anagrelide or hydroxyurea during this interval. HR observed in stratum 1 was CHR. Refer to Outcome Measure 20 for criteria for CHR. The Clopper and Pearson method was used to compute 95% exact CIs.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum1 Ph+ CP-CML (Dasatinib 60 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"All treated participants in stratum 1 who received at least 1 dose of dasatinib 60 mg/m\\^2.","reportingStatus":"POSTED","timeFrame":"Days 8, 15, 22, 29, 36, 43; Weeks 7, 13, 25, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63])","title":"Percentage of Participants With Confirmed Hematologic Response (HR) at Recommended Phase II Dose: Stratum 1 (Ph+ CP-CML)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}